Jonathan Alspaugh - Aug 16, 2021 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role
Chief Financial Officer
Signature
/s/ Steven Weber, by power of attorney
Stock symbol
AGLE
Transactions as of
Aug 16, 2021
Transactions value $
$262,660
Form type
4
Date filed
8/18/2021, 05:21 PM
Previous filing
Jul 8, 2021
Next filing
Dec 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGLE Common Stock Purchase $62.3K +9.78K $6.37* 9.78K Aug 16, 2021 Direct F1
transaction AGLE Common Stock Purchase $152K +23.4K +239.18% $6.50* 33.2K Aug 17, 2021 Direct F2
transaction AGLE Common Stock Purchase $48.4K +7.2K +21.71% $6.72* 40.4K Aug 18, 2021 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.13 to $6.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
F2 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.6 per share, inclusive.
F3 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.69 to $6.77 per share, inclusive.